Despite the theoretically suitable mechanism of anti-VEGF therapy and promising preclinical results [7,12,67], these therapeutic agents have failed to produce definitively favorable outcomes in glioblastoma patients [33,37,40,45]. Here, VEGFA is linked to glioblastoma.